Rebuilding the nigrostriatal dopamine pathway: 30 years and counting

Experimental Neurology

Volumn 256, Issue , 2014, Pages 21-24

  Collier, Timothy J ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; EPHRIN A5; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; SEMAPHORIN;

BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; CORPUS CALLOSUM; CORPUS STRIATUM; FOREBRAIN; HUMAN; MESENCEPHALON; NERVE FIBER GROWTH; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; AXONS; BRAIN TISSUE TRANSPLANTATION; DOPAMINERGIC NEURONS; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84904062975     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.03.011     Document Type: Note

References (49)

1. Bentlage C., Nikkah G., Cunningham M.G., Bjorklund A. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host. Exp. Neurol. 1999, 159:177-190.
2. Bjorklund A., Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 1979, 177:555-560.
3. Bjorklund A., Schmidt R.H., Stenevi U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res. 1980, 212:39-45.
4. Bjorklund A., Stenevi U., Schmidt R.H., Dunnett S.B., Gage F.H. Intracerebral grafing of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol. Scand. Suppl. 1983, 522:9-18.
5. Brecknell J.E., Du J.S., Muir E., Fidler P.S., Hlavin M.L., Dunnett S.B., Fawcett J.W. Bridge grafts of fibroblast growth factor-4-secreting schwannoma cells promote functional axonal regeneration in the nigrostriatal pathway of adult rat. Neurosci. 1996, 74:775-784.
6. Brecknell J.E., Haque N.S.K., Du J.-S., Muir E.M., Fidler P.S., Hlavin M.-L., Fawcett J.W., Dunnett S.B. Functional and anatomical reconstruction of the 6-hydroxydopamine lesioned nigrostriatal system of the adult rat. Neurosci. 1996, 71:913-925.
7. Brundin P., Isacson O., Gage F.H., Bjorklund A. Intrastriatal grafting of dopamine-containing neuronal cell suspensions: effects of mixing with target and non-target cells. Dev. Brain Res. 1986, 24:77-84.
8. Collier T.J., Sortwell C.E., Elsworth J.D., Taylor J.R., Roth R.H., Sladek J.R., Redmond D.E. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease. J. Comp. Neurol. 2002, 442:320-330.
9. DeBeaurepaire R., Freed W.J. Embryonic substantia nigra grafts innervate embryonic striatal co-grafts in preference to mature host striatum. Exp. Neurol. 1987, 95:448-454.
10. Diaz-Martinez N.E., Tamariz E., Diaz N.F., Garcia-Pena C.M., Varela-Echavarria A., Velasco I. Recovery from experimental parkinsonism by semaphorin-guided axonal growth of grafted dopamine neurons. Mol. Ther. 2013, 21:1579-1591.
11. Dunnett S.B., Bjorklund A., Schmidt R.H., Stenevi U., Iversen S.D. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol. Scand. Suppl. 1983, 522:29-37.
12. Dunnett S.B., Rogers D.C., Richards S.J. Nigrostriatal reconstruction after 6-OHDA lesions in rats: combination of dopamine-rich nigral grafts and nigrostriatal "bridge" grafts. Exp. Brain Res. 1989, 75:523-535.
13. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46months after transplantation for Parkinson's disease. N. Engl. J. Med. 1992, 327:1549-1555.
14. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
15. Gaillard A., Decressac M., Frappe I., Fernagut P.O., Prestoz L., Besnard S., Jaber M. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Neurobiol. Dis. 2009, 35:477-488.
16. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease. Arch. Neurol. 1999, 56:179-187.
17. Hoffman P.C., Hemmendinger L.M., Kotake C., Heller A. Enhanced dopamine cell survival in reaggregates containing telencephalic targets. Brain Res. 1983, 274:275-281.
18. Jin Y., Zhang C., Ziemba K.S., Goldstein G.A., Sullivan P.G., Smith G.M. Directing dopaminergic fiber growth along a preformed molecular pathway from embryonic ventral mesencephalon transplants in the rat brain. J. Neurosci. Res. 2011, 89:619-627.
19. Kordower J.H., Bjorklund A. Trophic factor gene therapy for Parkinson's disease. Mov. Disord. 2013, 28:96-109.
20. Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., Halliday G.M., Bartus R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136:2419-2431.
21. Lin L., Rao Y., Isacson O. Netrin-1 and slit-2 regulate and direct neurite growth of ventral midbrain dopaminergic neurons. Mol. Cell. Neurosci. 2005, 28:547-555.
22. Lindvall O., Rehncrona S., Brundin P., Gustavii B., Astedt B., Widner H., et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 1989, 46:615-631.
23. Lindvall O., Sawle G., Widner H., Rothwell J.C., Bjorklund A., Brooks D., et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 1994, 35:172-180.
24. Madrazo I., Leon V., Torres C., Aguilera M.C., Varela G., Alvarez F., et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N. Engl. J. Med. 1988, 318:51.
25. Mendez I., Hong M. Reconstruction of the striato-nigro-striatal circuitry by simultaneous double dopaminergic grafts: a tracer study using fluorogold and horseradish peroxidase. Brain Res. 1997, 778:194-205.
26. Mendez I., Sadi D., Hong M. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J. Neurosci. 1996, 16:7216-7227.
27. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
28. Perlow M.J., Freed W.J., Hoffer B.J., Seiger A., Olson L., Wyatt R.J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979, 204:643-647.
29. Peschanski M., Defer G., N'Guyen J.P., Ricolfi F., Monfort J.C., Remy P., et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994, 117:487-499.
30. Piccini P., Brooks D.J., Bjorklund A., Gunn R.N., Grasby P.M., Rimoldi O., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 1999, 2:1137-1140.
31. Prestoz L., Jaber M., Gaillard A. Dopaminergic axon guidance: which makes what?. Front. Cell Neurosci. 2012, 6:1-13.
32. Prochiantz A.U., DiProzio U., Kato A., Berger B., Glowinski J. In vitro maturation of mesencephalic dopaminergic neurons from mouse embryos is enhanced in the presence of their striatal target cells. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:5387-5391.
33. Redmond D.E., Elsworth J.D., Roth R.H., Leranth C., Collier T.J., Blanchard B., et al. Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF. J. Comp. Neurol. 2009, 515:31-40.
34. Sawamoto K., Nakao N., Kobayashi K., Matsushita N., Takahashi H., Kakishita K., et al. Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons. PNAS 2001, 98:6423-6428.
35. Schmidt R.H., Bjorklund A., Stenevi U., Dunnett S.B., Gage F.H. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol. Scand. Suppl. 1983, 522:19-28.
36. Sladek J.R., Collier T.J., Elsworth J.D., Taylor J.R., Roth R.H., Redmond D.E. Can graft-derived neurotrophic activity be used to direct axonal outgrowth of grafted dopamine neurons for circuit reconstruction in primates?. Exp. Neurol. 1993, 124:134-139.
37. Sladek J.R., Bjugstad K.B., Collier T.J., Bundock E.A., Blanchard B.C., Elsworth J.D., Roth R.H., Redmond D.E. Embryonic substantia nigra grafts show directional outgrowth to cografted striatal grafts and potential for pathway reconstruction in nonhuman primate. Cell Transplant. 2008, 17:1-18.
38. Sortwell C.E., Collier T.J., Sladek J.R. Co-grafted embryonic striatum increases the survival of grafted embryonic dopamine neurons. J. Comp. Neurol. 1998, 399:530-540.
39. Spencer D.D., Robbins R.J., Naftolin F., Marek K.L., Vollmer T., Leranth C., et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N. Engl. J. Med. 1992, 327:1541-1548.
40. Steece-Collier K., Rademacher D.J., Soderstrom K. Anatomy of graft-induced dyskinesias: circuit remodeling in the parkinsonian striatum. Basal Ganglia 2012, 2:15-30.
41. Thompson L.H., Grealish S., Kirik D., Bjorklund A. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse. Eur. J. Neurosci. 2009, 30:625-638.
42. Tomozawa Y., Appel S.H. Soluble striatal extracts enhance development of mesencephalic dopaminergic neurons in vitro. Brain Res. 1986, 399:111-124.
43. Wang Y., Tien L.T., Lapchak P.A., Hoffer B.J. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA lesioned rats. Cell Tissue. Res. 1996, 286:225-233.
44. Wenning G.K., Odin P., Morrish P., Rehncrona S., Widner H., Brundin P., et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 1997, 42:95-107.
45. Yurek D.M., Collier T.J., Sladek J.R. Embryonic mesencephalic and striatal co-grafts: development of grafted dopamine neurons and functional recovery. Exp. Neurol. 1990, 109:191-199.
46. Zhang C., Jin Y., Ziemba K.S., Fletcher A.M., Ghosh B., Truit E., Yurek D.M., Smith G.M. Long distance directional growth of dopaminergic axons along pathways of netrin-1 and GDNF. Exp. Neurol. 2013, 250:156-164.
47. Zhou F.C., Chiang Y.H. Excitochemical-induced trophic bridging directs axonal outgrowth of transplanted neurons to distal target. Cell Transplant. 1995, 4:103-112.
48. Zhou F.C., Chiang Y.H., Wang Y. Constructing a new nigrostriatal pathway in the parkinsonian model with bridged neural transplantation in substantia nigra. J. Neurosci. 1996, 16:6965-6974.
49. Zigmond M.J., Berger T.W., Grace A.A., Stricker E.M. Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism. Mol. Chem. Neuropathol. 1989, 10:185-200.